BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.
- National rollout of Avantect tests through Sonic Healthcare and Healius networks
- Initial Medicare reimbursement application submitted to MSAC for pancreatic cancer test
- BREASTESTplus 2.0 developed with improved accuracy and broader market
- Board strengthened with appointment of healthcare technology expert Mark McConnell
- Cash balance of $2.36 million with ongoing R&D investment and funding plans
National Avantect Rollout Gains Traction
BCAL Diagnostics (ASX:BDX) has taken a significant step in commercialising its early cancer detection tests by rolling out the Avantect Pancreatic and Ovarian blood tests nationally. Since launching in January 2026 at the Sydney Breast Clinic, the tests have been made available through Sonic Healthcare collection centres in New South Wales, Queensland, and Victoria, as well as nationally via the Healius Pathology Network. This expanded access generated $88,000 in revenue from 91 tests during the March quarter, signalling early market acceptance.
The rollout builds on the company’s earlier efforts to broaden access and follows a recent expansion of pathology partnerships, which has been instrumental in increasing test availability across Australia. This momentum is further reflected in strong engagement with the digital platform EarlyDetection.com.au, which has attracted nearly 2,000 enquiries from healthcare professionals and patients alike, highlighting a growing awareness and demand for early cancer detection solutions.
These developments complement BCAL’s strategy to diversify its product portfolio and grow revenue streams through innovative blood tests, as detailed in its previous national Avantect expansion announcement.
Medicare Reimbursement Application Marks Regulatory Milestone
In a move that could materially impact patient access and adoption, BCAL submitted an initial application to the Medical Services Advisory Committee (MSAC) seeking Medicare Benefits Schedule reimbursement for the Avantect pancreatic cancer test targeting 'at risk' individuals. This submission is underpinned by clinical validation data and advocacy support, representing a crucial step toward establishing a sustainable reimbursement pathway in Australia.
The timing and outcome of the MSAC review remain uncertain, but securing Medicare reimbursement would likely enhance affordability and uptake, addressing a significant barrier in early cancer diagnostics.
BREASTESTplus 2.0 Expands Market Reach and Clinical Utility
BCAL has also advanced its flagship breast cancer detection test with the development of BREASTESTplus 2.0, which features improved accuracy and is designed for use in all women over 30 years old, regardless of breast density. This contrasts with the initial version launched in Sydney, which was limited to women with high breast density and required mammogram confirmation.
The new test has demonstrated high sensitivity and negative predictive value across all breast density categories and early-stage breast cancer, including ductal carcinoma in situ (Stage 0). The broader applicability effectively doubles the addressable market and has been well received by clinicians, patients, and advocacy groups. BCAL plans a national commercial launch starting in Q1 FY27, targeting major cities including Melbourne, Sydney, Brisbane, and the Gold Coast, with expansion into Adelaide and Perth planned for Q2 FY27.
Governance and Financial Position
Strengthening its leadership, BCAL appointed Mark McConnell, a business developer with extensive experience scaling healthcare technology firms, to its board in February 2026. This move aligns with the company’s ambitions for commercial growth and capital market engagement.
On the financial front, BCAL reported a cash balance of $2.36 million at quarter-end, following $0.9 million invested in research and development and $1.2 million in overheads. The company’s operating cash flow remains negative, with an estimated funding runway of approximately 1.6 quarters without additional financing. However, BCAL has a $5.1 million convertible note facility, with $4.1 million drawn and $1 million available, and is actively engaging potential investors to secure further funding. The company also benefits from a research and development tax offset, supporting its cash flow management.
Clinical and Advocacy Engagements Support Market Access
BCAL continues to invest in clinician education and engagement, integrating its testing services within widely used clinical software platforms to facilitate adoption. It collaborates with leading clinicians such as Dr Stephen Robson, Professor Jas Samra, and Dr Greg Gard to support clinical uptake and evidence generation.
Advocacy efforts remain robust, with partnerships involving Pancare Foundation, Pankind, and Breast Cancer Network of Australia, alongside government engagement through parliamentary groups focused on breast, ovarian, and pancreatic cancers. These initiatives aim to raise awareness and promote equitable access to early detection diagnostics.
Bottom Line?
BCAL’s progress in commercial rollout and reimbursement efforts positions it for growth, but limited cash reserves and the pending MSAC decision pose near-term challenges.
Questions in the middle?
- How quickly will Medicare reimbursement be granted for the Avantect pancreatic cancer test?
- Can BCAL scale sales of BREASTESTplus 2.0 to capture the expanded market effectively?
- What funding strategies will BCAL deploy to extend its cash runway beyond 1.6 quarters?